Literature DB >> 18647323

Differential effects of ifosfamide on dendritic cell-mediated stimulation of T cell interleukin-2 production, natural killer cell cytotoxicity and interferon-gamma production.

M C Kuppner1, E Bleifuss, E Noessner, R Mocikat, C von Hesler, C Mayerhofer, R D Issels.   

Abstract

Ifosfamide is a DNA-alkylating agent used frequently in chemotherapy of human malignancies. Ifosfamide and its major decomposition products deplete intracellular glutathione (GSH). Glutathione is the major intracellular thiol reductant that protects cells against oxidative injury. Ifosfamide depletion of intracellular GSH in human dendritic cells (DC), T cells and natural killer (NK) cells impairs their functional activity which can be restored by reconstituting GSH. Here we assessed the effect of ifosfamide on DC-mediated stimulation of NK cell proliferation via T cells and on direct DC stimulation of NK cell cytotoxicity and interferon (IFN)-gamma production. Indirect DC stimulation of NK cell proliferation via T cells and T cell-derived interleukin (IL)-2 were reduced by ifosfamide treatment of DC and reconstitution of GSH in DC restored both responses. When DC and NK cells were treated with ifosfamide, DC could overcome the negative effect of ifosfamide on NK cytotoxic function whereas NK cell IFN-gamma production was less efficiently restored. The ability of IL-2 activated NK cells to kill autologous immature DC or to induce DC maturation was reduced moderately by treatment of both cell types with ifosfamide. Overall, our results suggest that DC may stimulate anti-tumour effector cells in patients even if they had received treatment with chemotherapeutic agents such as ifosfamide.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18647323      PMCID: PMC2527363          DOI: 10.1111/j.1365-2249.2008.03708.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  29 in total

1.  Influence of thiols on thermosensitivity of mammalian cells in vitro.

Authors:  R D Issels; A Nagele
Journal:  Methods Enzymol       Date:  1990       Impact factor: 1.600

2.  Lymphocyte proliferation in glutathione-depleted lymphocytes: direct relationship between glutathione availability and the proliferative response.

Authors:  D L Hamilos; P Zelarney; J J Mascali
Journal:  Immunopharmacology       Date:  1989 Nov-Dec

3.  Glutathione regulates interleukin-2 activity on cytotoxic T-cells.

Authors:  C M Liang; N Lee; D Cattell; S M Liang
Journal:  J Biol Chem       Date:  1989-08-15       Impact factor: 5.157

Review 4.  Ifosfamide--pharmacology, safety and therapeutic potential.

Authors:  W P Brade; K Herdrich; M Varini
Journal:  Cancer Treat Rev       Date:  1985-03       Impact factor: 12.111

Review 5.  Glutathione.

Authors:  A Meister; M E Anderson
Journal:  Annu Rev Biochem       Date:  1983       Impact factor: 23.643

6.  High-performance liquid chromatography analysis of nanomole levels of glutathione, glutathione disulfide, and related thiols and disulfides.

Authors:  D J Reed; J R Babson; P W Beatty; A E Brodie; W W Ellis; D W Potter
Journal:  Anal Biochem       Date:  1980-07-15       Impact factor: 3.365

7.  The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo.

Authors:  M J Lind; A T McGown; J A Hadfield; N Thatcher; D Crowther; B W Fox
Journal:  Biochem Pharmacol       Date:  1989-06-01       Impact factor: 5.858

8.  Requirement of thiol compounds as reducing agents for IL-2-mediated induction of LAK activity and proliferation of human NK cells.

Authors:  A Yamauchi; E T Bloom
Journal:  J Immunol       Date:  1993-11-15       Impact factor: 5.422

Review 9.  Ifosfamide clinical pharmacokinetics.

Authors:  T Wagner
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

Review 10.  Biology of natural killer cells.

Authors:  G Trinchieri
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

View more
  5 in total

1.  Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages.

Authors:  Ilia N Buhtoiarov; Paul M Sondel; Jon M Wigginton; Tatiana N Buhtoiarova; Eric M Yanke; David A Mahvi; Alexander L Rakhmilevich
Journal:  Immunology       Date:  2010-10-13       Impact factor: 7.397

2.  PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics.

Authors:  Daniella Lowenberg; Caroline F Thorn; Zeruesenay Desta; David A Flockhart; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-02       Impact factor: 2.089

3.  Hepatitis B Reactivation After Ifosfamide Therapy for Retroperitoneal Sarcoma.

Authors:  Purva Chhibar; Ziqiang Zhu; Naga K S Cheedella; Rashid Chaudhry; Jen Chin Wang
Journal:  Am J Case Rep       Date:  2016-06-01

Review 4.  Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response.

Authors:  Elisa C Toffoli; Abdolkarim Sheikhi; Yannick D Höppner; Pita de Kok; Mahsa Yazdanpanah-Samani; Jan Spanholtz; Henk M W Verheul; Hans J van der Vliet; Tanja D de Gruijl
Journal:  Cancers (Basel)       Date:  2021-02-09       Impact factor: 6.639

5.  Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects.

Authors:  Nathalie Chaput; Angelo Paci; Julia Delahousse; Charles Skarbek; Mélanie Desbois; Jean-Luc Perfettini
Journal:  J Immunother Cancer       Date:  2020-08       Impact factor: 13.751

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.